Objective: Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves’ disease (GD), DCs have more vigorous immune responses than those in healthy controls. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on the maturation of DC in GD patients. This study aims to evaluate the effect of oral alfacalcidol (1α-D3) on DC maturation in GD patients. Methods: 25 GD patients with thyrotoxicosis were divided into 2 groups: 12 GD patients receiving oral 1α-D3 and 13 GD patients receiving placebo, in addition to the treatment of propylthiouracil. Comparison of DC maturation was performed before and after the oral 1α-D3. DC maturation was evaluated based on the expression of DC markers (HLA-DR, CD80, CD40, CD83, CD14, and CD206) and the ratio of cytokines interleukin-12 (IL-12)/IL-10. Results: After 8 weeks, 8 out of 12 GD patients in the treatment group and 6 out of 13 GD patients in the placebo group still had high fT4 level. The expression of CD80 decreased (p=0.48) and CD206 increased (p=0.47) insignificantly among treatment group. The IL-12/IL-10 ratio decreased along with the improvement of fT4 level in both groups. No difference in the IL-12/IL-10 ratio between treatment and placebo group. Conclusion: The effects of oral 1α-D3 on DC maturation of GD patients have not been clearly demonstrated in this study yet.
|Number of pages||5|
|Journal||Asian Journal of Pharmaceutical and Clinical Research|
|Publication status||Published - 2017|
- Dendritic cells
- Graves’ disease
- Vitamin D